Skip to content
Evigrade
CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Second-generation systemic triazole antifungal

Updated · Methodology

Mechanism

Posaconazole is a strong CYP3A4 inhibitor and can markedly increase exposure to drugs that CYP3A4 metabolises (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The posaconazole SmPC lists cisapride among CYP3A4 substrates whose plasma levels may rise with posaconazole. This leads to prolongation of the corrected QT interval (QTc) and, in rare cases, torsade de pointes (posaconazole SmPC, EMA). The posaconazole documents give no study figures for this pair. Some azole antifungals, including posaconazole, have been associated with QT prolongation, and cases of torsade de pointes have been reported in people taking posaconazole (posaconazole label, US Food and Drug Administration, FDA). In healthy volunteers, however, the mean QTc did not increase with posaconazole (posaconazole FDA label).

Symptoms

The danger of the combination is prolongation of the corrected QT interval (QTc) and, rarely, torsade de pointes (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. Proarrhythmic conditions in the posaconazole SmPC include congenital or acquired QTc prolongation, cardiomyopathy (especially with heart failure), sinus bradycardia and pre-existing symptomatic arrhythmias (posaconazole SmPC, EMA).

Management

The combination is contraindicated. The posaconazole summaries of product characteristics (SmPCs), for both the tablets and the oral suspension, list cisapride by name among contraindicated CYP3A4 substrates that prolong the QT interval (posaconazole SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The US posaconazole label contraindicates CYP3A4 substrates that prolong the QT interval and names pimozide and quinidine, but not cisapride (posaconazole label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the posaconazole documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe posaconazole with it (posaconazole SmPC, EMA). No document states how long to wait after stopping posaconazole before starting cisapride. The mean half-life of posaconazole is 29 hours for the tablets and 35 hours for the suspension (posaconazole SmPCs, EMA). Monitor potassium, magnesium and calcium and correct them as needed before and during posaconazole treatment (posaconazole SmPCs, EMA, and FDA label). Use posaconazole with caution in congenital or acquired QTc prolongation, cardiomyopathy (especially with heart failure), sinus bradycardia and symptomatic arrhythmias (posaconazole SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cisapride

Other interactions with Posaconazole